Advertisement

Archives of Gynecology and Obstetrics

, Volume 298, Issue 4, pp 797–804 | Cite as

Participation of elderly gynecological cancer patients in clinical trials

  • Katharina Prieske
  • Fabian Trillsch
  • Gülten Oskay-Özcelik
  • Radoslav Chekerov
  • Christiane Bleich
  • Leticia Oliveira-Ferrer
  • Donata Grimm
  • Sascha Kuerti
  • Volkmar Mueller
  • Anna Suling
  • Barbara Schmalfeldt
  • Jalid Sehouli
  • Sven Mahner
  • Linn Woelber
Gynecologic Oncology

Abstract

Background

Elderly patients are underrepresented in clinical trials in gynecological cancer, even though they are disproportionally often affected. This study aimed to evaluate the disposition and apprehension of elderly patients toward study participation.

Methods

112 elderly gynecological cancer patients (median age 70) were surveyed in a multicenter cross-sectional study. Besides fitness, state of disease, education and domestic situation, questions aimed at the general willingness to participate in a clinical trial. Personal reasons for refusal and anticipated advantages/disadvantages that might evolve from participation were inquired.

Results

Willingness to participate in a clinical study was generally high (72%, 74/102). Reasons for potential study participation were: ‘better monitoring of the disease’ (67.1%), ‘better medical care’ (46.1%), ‘to help medical research’ (44.7%), ‘better medication’ (35.5%) and ‘because of my doctor’s recommendation’ (22.4%). Reasons for potential refusal were: ‘too time consuming’ (24.4%), ‘fear of side effects’ (21.8%), ‘misuse as experimental animal’ (18%), ‘long distance to clinic’ (14.1%) and ‘too little or unclear information’ (10.3%). 37.2% (29/78) of the patients stated that they had ‘no objection’ at all against study participation. The question if patients anticipated having a longer life due to study participation was answered with ‘yes’ or ‘rather yes’ in 42% (38/90); 28.9% answered ‘no’ or ‘rather no’ (29% undecided). No statistical significant relation between willingness to participate in a study and general fitness (p = 0.133), education (p = 0.122), age (p = 0.474) or domestic situation (p = 0.123) could be observed in a multivariate logistic regression model.

Conclusions

Elderly patients are generally willing to participate in clinical studies, in our cohort regardless of their fitness. Benefits of participation seem to be unclear among a majority of potential study participants. Therefore, it might be decisive to provide more general information regarding benefits and safety for elderly patients in a clinical trial.

Keywords

Elderly Chemotherapy Gynecology Clinical trial 

Notes

Acknowledgements

Medac Oncology (Grant number ID0EKBAG3598).

Author contributions

KP: study design, analysis of data and writing the manuscript (original draft); FT: organization of the survey, writing and approving the manuscript; GO-Ö: study design, design of questionnaire, organization of the survey and writing and approving the manuscript; RC: writing and approving the manuscript; CB: study design, design of questionnaire and writing and approving the manuscript; LO-F: writing and approving the manuscript; DG: writing and approving the manuscript; SK: figure design and writing and approving the manuscript; VM: writing and approving the manuscript; AS: statistical advice and analysis, and writing and approving the manuscript; BS: writing and approving the manuscript; JS: study design, design of questionnaire, organization of the survey and writing and approving the manuscript; SM: study design, design of questionnaire, organization of the survey and writing and approving the manuscript; LW: study design, organization of the survey, analysis of data and writing the manuscript (original draft).

Compliance with ethical standards

Conflict of interest

All authors declare that there are no conflicts of interest involved with the presented data. This study was supported by Medac Oncology without restriction in protocol or analysis.

References

  1. 1.
    Talarico L, Chen G, Pazdur R (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22(22):4626–4631CrossRefPubMedGoogle Scholar
  2. 2.
    Villella J, Chalas E (2005) Optimising treatment of elderly patients with ovarian cancer: improving their enrollment in clinical trials. Drugs Aging 22(2):95–100CrossRefPubMedGoogle Scholar
  3. 3.
    Lara PN Jr et al (2005) Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 23(36):9282–9289CrossRefPubMedGoogle Scholar
  4. 4.
    Mathews C et al (2009) Willingness of gynecologic cancer patients to participate in clinical trials. Gynecol Oncol 112(1):161–165CrossRefPubMedGoogle Scholar
  5. 5.
    Comis RL et al (2003) Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830–835CrossRefPubMedGoogle Scholar
  6. 6.
    Colon-Otero G et al (2008) Disparities in participation in cancer clinical trials in the United States: a symptom of a healthcare system in crisis. Cancer 112(3):447–454CrossRefPubMedGoogle Scholar
  7. 7.
    Donnelly CB et al (2017) A population-level investigation of cancer clinical trials participation in a UK region. Eur J Cancer Prev 26:S229–S235CrossRefPubMedGoogle Scholar
  8. 8.
    Jimenez R et al (2013) Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment? J Palliat Med 16(3):256–262CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gross CP et al (2004) Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 96(14):1063–1069CrossRefPubMedGoogle Scholar
  10. 10.
    Bell JA, Balneaves LG (2015) Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer 23(4):1169–1196CrossRefPubMedGoogle Scholar
  11. 11.
    Roick J et al (2017) Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care 27:e12645CrossRefGoogle Scholar
  12. 12.
    Ellis PM et al (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19(15):3554–3561CrossRefPubMedGoogle Scholar
  13. 13.
    Go RS et al (2006) Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106(2):426–433CrossRefPubMedGoogle Scholar
  14. 14.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRefGoogle Scholar
  15. 15.
    Du Bois A, Pfisterer J, Kellermann L, Kreienberg R (2001) Treatment of advanced ovarian cancer in Germany: the impact of participation in clinical trials. Geburtshilfe und Frauenheilkunde 61:863–871.  https://doi.org/10.1055/s-2001-19177 CrossRefGoogle Scholar
  16. 16.
    Woopen H et al (2016) Elderly ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). Eur J Cancer 60:101–106CrossRefPubMedGoogle Scholar
  17. 17.
    Tinquaut F et al (2016) Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials. Gynecol Oncol 143(1):22–26CrossRefPubMedGoogle Scholar
  18. 18.
    Vercelli M et al (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol 35(3):161–179CrossRefPubMedGoogle Scholar
  19. 19.
    Stewart JH et al (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14(12):3328–3334CrossRefPubMedGoogle Scholar
  20. 20.
    Velikova G et al (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4):714–724CrossRefPubMedGoogle Scholar
  21. 21.
    Lewis JH et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389CrossRefPubMedGoogle Scholar
  22. 22.
    Marcus MW et al (2014) Factors associated with dropout in a lung cancer high risk cohort—the Liverpool Lung Project. Int J Oncol 44(6):2146–2152CrossRefPubMedGoogle Scholar
  23. 23.
    Baquet CR et al (2006) Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev 30(1):24–33CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Peterson JC et al (2012) Attrition in longitudinal randomized controlled trials: home visits make a difference. BMC Med Res Methodol 12:178CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Harter P et al (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16(11):1801–1805CrossRefPubMedGoogle Scholar
  26. 26.
    Hilpert F et al (2012) Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience. Onkologie 35(3):76–81CrossRefPubMedGoogle Scholar
  27. 27.
    Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Katharina Prieske
    • 1
  • Fabian Trillsch
    • 1
    • 2
  • Gülten Oskay-Özcelik
    • 3
  • Radoslav Chekerov
    • 4
  • Christiane Bleich
    • 5
  • Leticia Oliveira-Ferrer
    • 1
  • Donata Grimm
    • 1
  • Sascha Kuerti
    • 1
  • Volkmar Mueller
    • 1
  • Anna Suling
    • 6
  • Barbara Schmalfeldt
    • 1
  • Jalid Sehouli
    • 4
  • Sven Mahner
    • 1
    • 2
  • Linn Woelber
    • 1
  1. 1.Department of Gynecology and Gynecologic OncologyUniversity Medical Centre Hamburg-EppendorfHamburgGermany
  2. 2.Department of Obstetrics and Gynecology, University HospitalLMU MunichMunichGermany
  3. 3.Private Practice for Gynecologic OncologyBerlinGermany
  4. 4.Department of Gynecology and Gynecologic OncologyCharité Campus VirchowBerlinGermany
  5. 5.Department of Medical PsychologyUniversity Medical Centre Hamburg-EppendorfHamburgGermany
  6. 6.Department of BiometricsUniversity Medical Centre Hamburg-EppendorfHamburgGermany

Personalised recommendations